Richard Fei
Pulmonary Disease · Lafayette, LANPI 1265428585
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 205 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 22.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,811 and has fallen 98.2% since, to $33 in 2023. That places this record below the midpoint for pulmonary disease clinicians in LA, where the typical reported total is $3,696.
Across 205 payments — averaging $15.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$708
- Sunovion Pharmaceuticals Inc.$535
- Mylan Specialty L.p.$289
- AstraZeneca$258
- Getinge USA Sales, LLC$192
- Grifols USA, LLC$143
- plus $1K from 17 others
What the payments were for
- Food & beverage$3,131100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 53 | $708 |
| Sunovion Pharmaceuticals Inc. | 47 | $535 |
| Mylan Specialty L.p. | 16 | $289 |
| AstraZeneca | 16 | $258 |
| Getinge USA Sales, LLC | 6 | $192 |
| Grifols USA, LLC | 9 | $143 |
| Genentech USA, Inc. | 7 | $142 |
| Sanofi | 6 | $139 |
| Actelion Pharmaceuticals US, Inc. | 7 | $127 |
| Gilead | 7 | $105 |
| Novartis | 6 | $94 |
| Boehringer Ingelheim | 5 | $83 |
| Regeneron Healthcare Solutions, Inc. | 3 | $59 |
| Insmed, Inc. | 3 | $43 |
| United Therapeutics Corporation | 2 | $39 |
| Johnson & Johnson | 3 | $36 |
| Teva Pharmaceuticals USA, Inc. | 2 | $36 |
| Merck | 2 | $25 |
| Mallinckrodt Hospital Products Inc. | 1 | $23 |
| Circassia Inc. | 1 | $19 |
| Bayer | 1 | $18 |
| Cook Medical LLC | 1 | $17 |
| La Jolla Pharmaceutical Company | 1 | $12 |
How this compares
$3,143 in reported general payments places this provider in the 45th percentile of 189 pulmonary disease providers in Louisiana.
Other pulmonary disease in Lafayette
- Frank CourmierLafayette$15K
- Timothy KeysLafayette$14K
- Walter BrownLafayette$12K
- Billy RossonLafayette$11K
- George GuidryLafayette$9K
- Andrea EspinozaHouma$655K
- Joseph LaskyNew Orleans$447K
- Hollis O NealBaton Rouge$418K
- Ramsy AbdelghaniNew Orleans$308K
- Juzar AliNew Orleans$216K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.